Establishment of a new canine inflammatory mammary carcinoma cell line and analysis of its cystine-glutamate transporter subunit expression
Author:
Itoh Harumichi1, Naruse Ryo1, Tani Kenji2, Sunahara Hiroshi2, Nemoto Yuki2, Nakaichi Munekazu3, Iseri Toshie3, Horikirizono Hiro3, Itamoto Kazuhito1
Affiliation:
1. Department of Small Animal Clinical Science, Joint Faculty of Veterinary Medicine, Yamaguchi University , 1677-1 Yoshida , Yamaguchi , Japan 2. Department of Veterinary Surgery, Joint Faculty of Veterinary Medicine, Yamaguchi University , 1677-1 Yoshida , Yamaguchi , Japan 3. Laboratory of Veterinary Radiology, Yamaguchi University , 1677-1 Yoshida , Yamaguchi , Japan
Abstract
Abstract
Introduction
Inflammatory mammary carcinoma (IMC) is a rare disease with a poor prognosis and one affecting dogs. Inflammatory breast carcinoma (IBC) is a subtype of malignant breast cancer in humans with a high degree of malignancy and a similarly poor prognosis. Since the clinical symptoms and prognoses of both are similar, canine IMC has been considered as a model of human IBC. In this study, we newly established a stable IMC-derived cell line from a patient at the Yamaguchi University Animal Medical Center in Japan.
Material and Methods
The patient was a female toy poodle presenting with an inflamed mammary gland, which was diagnosed as IMC. The cell line was established from a tissue biopsy. Surface antigen marker (CD24 and CD44) expression was determined. Cystine/glutamate antiporter (xCT) expression was determined by Western blotting, flow cytometry and fluorescence immunostaining, and sulfasalazine was administered to ascertain if it suppressed xCT expression. Stem cell marker (Nanog, Sox2, Myc and Klf4) expression and aldehyde dehydrogenase (ALDH) activity were also investigated.
Results
The cultured cells showed xCT, and its suppression showed downregulation of stem cell markers and ALDH activity. Stable cell proliferation was verified.
Conclusion
A new canine IMC-derived cell line was established. In the future, we aim to study the effect of xCT on the maintenance of cancer stem cell properties in canine tumours, and propose a new therapeutic method for the treatment of canine IMC by targeting xCT.
Publisher
Walter de Gruyter GmbH
Subject
General Veterinary
Reference35 articles.
1. Bonnet D., Dick J.E.: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3, 730–737, doi: 10.1038/nm0797-730. 2. Boughey J.C., Gonzalez R.J., Bonner E., Kuerer H.M.: Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 2007, 12, 1276–1287, doi: 10.1634/theoncologist.12-11-1276. 3. Caceres S., Pena L., de Andres P.J., Illera M.J., Lopez M.S., Woodward W.A., Reuben J.M., Illera J.C.: Establishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366. PLoS One 2015, 10, e0122277, doi: 10.1371/journal.pone.0122277. 4. Caceres S., Pena L., Lacerda L., Illera M.J., de Andres P.J., Larson R.A., Gao H., Debeb B.G., Woodward W.A., Reuben J.M., Illera J.C.: Canine cell line, IPC-366, as a good model for the study of inflammatory breast cancer. Vet Comp Oncol 2017, 15, 980–995, doi: 10.1111/vco.12238. 5. de Mello Souza C.H., Toledo-Piza E., Amorin R., Barboza A., Tobias K.M.: Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment. Can Vet J 2009, 50, 506–510.
|
|